Novo Nordisk A/S (CO:NOVO-B) — Market Cap & Net Worth
Market Cap & Net Worth: Novo Nordisk A/S (NOVO-B)
Novo Nordisk A/S (CO:NOVO-B) has a market capitalization of $136.53 Billion (Dkr872.63 Billion) as of September 23, 2026. Listed on the CO stock exchange, this Denmark-based company holds position #177 globally and #1 in its home market, demonstrating a -7.70% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Novo Nordisk A/S's stock price Dkr258.80 by its total outstanding shares 3371844674 (3.37 Billion). Also see Novo Nordisk A/S assets under control for a full breakdown of the balance sheet.
Novo Nordisk A/S Market Cap History: 2015 to 2026
Novo Nordisk A/S's market capitalization history from 2015 to 2026. Data shows growth from $86.54 Billion to $136.53 Billion (5.00% CAGR). Also see cash efficiency ratio of Novo Nordisk A/S for how efficiently the company converts equity into cash flow.
Index Memberships
Novo Nordisk A/S is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
STOXX Europe Large 200 EUR Price
LCXP
|
$7.26 Trillion | 1.88% | #15 of 182 |
|
STOXX Europe Large 200 Net Return
LCXR
|
$7.26 Trillion | 1.88% | #15 of 182 |
Weight: Novo Nordisk A/S's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Novo Nordisk A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Novo Nordisk A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Novo Nordisk A/S for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.56x
Novo Nordisk A/S's market cap is 0.56 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.68x
Novo Nordisk A/S's market cap is 1.68 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $56.64 Billion | $111.78 Billion | $37.92 Billion | 0.51x | 1.49x |
| 2017 | $76.66 Billion | $111.70 Billion | $38.13 Billion | 0.69x | 2.01x |
| 2018 | $70.08 Billion | $111.83 Billion | $38.63 Billion | 0.63x | 1.81x |
| 2019 | $93.15 Billion | $122.02 Billion | $38.95 Billion | 0.76x | 2.39x |
| 2020 | $105.04 Billion | $126.95 Billion | $42.14 Billion | 0.83x | 2.49x |
| 2021 | $184.48 Billion | $140.80 Billion | $47.76 Billion | 1.31x | 3.86x |
| 2022 | $241.63 Billion | $176.95 Billion | $55.52 Billion | 1.37x | 4.35x |
| 2023 | $364.24 Billion | $232.26 Billion | $83.68 Billion | 1.57x | 4.35x |
| 2024 | $329.30 Billion | $290.40 Billion | $100.99 Billion | 1.13x | 3.26x |
| 2025 | $171.59 Billion | $309.06 Billion | $102.43 Billion | 0.56x | 1.68x |
Competitor Companies of NOVO-B by Market Capitalization
Companies near Novo Nordisk A/S in the global market cap rankings as of September 23, 2026. Review tangible net worth ratio of Novo Nordisk A/S to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Novo Nordisk A/S by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $1.04 Trillion USD.
- Eli Lilly and Company (SA:LILY34): Ranked #20 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Johnson & Johnson (NYSE:JNJ): Ranked #29 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #46 globally with a market cap of $356.49 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $1.04 Trillion | $1170.14 |
| #20 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #29 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $269.19 |
| #46 | AbbVie Inc | NYSE:ABBV | $356.49 Billion | $265.21 |
Novo Nordisk A/S Historical Marketcap From 2015 to 2026
Between 2015 and today, Novo Nordisk A/S's market cap moved from $86.54 Billion to $ 136.53 Billion, with a yearly change of 5.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Dkr136.53 Billion | -20.43% |
| 2025 | Dkr171.59 Billion | -47.89% |
| 2024 | Dkr329.30 Billion | -9.59% |
| 2023 | Dkr364.24 Billion | +50.74% |
| 2022 | Dkr241.63 Billion | +30.98% |
| 2021 | Dkr184.48 Billion | +75.62% |
| 2020 | Dkr105.04 Billion | +12.77% |
| 2019 | Dkr93.15 Billion | +32.92% |
| 2018 | Dkr70.08 Billion | -8.60% |
| 2017 | Dkr76.66 Billion | +35.35% |
| 2016 | Dkr56.64 Billion | -34.55% |
| 2015 | Dkr86.54 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Novo Nordisk A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $136.53 Billion USD |
| MoneyControl | $136.53 Billion USD |
| MarketWatch | $136.53 Billion USD |
| marketcap.company | $136.53 Billion USD |
| Reuters | $136.53 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products i… Read more